MaxCyte provides FY2024 guidance: core flat to +5%; FY2023 prelim core down 25% YoY

MAXCYTE, INC.

FY2023 prelim total revenue $41.1-$41.3M (vs $44.3M in 2022); core revenue $29.6-$29.8M (vs $39.6M), down ~25%.
SPL program-related revenue was ~$11.4M in FY2023 (vs $4.6M in 2022), driven by licensing.
FY2024 guidance: core flat to +5%; SPL ~$3M; outlook does not include CASGEVY royalties.
Year-end 2023 cash & investments ~$210M; expects to end 2024 with ~$175M.
Already signed three SPLs in 2024; presenting at Cowen conference March 5.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. reported fiscal year ended December 31, 2023 results: revenue between $41.1 million and $41.3 million.

Period: fiscal year ended December 31, 2023
Revenue: between $41.1 million and $41.3 million
Result: preliminary results

Exact text from the filing

Total revenue for the fiscal year of 2023 is expected to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-002480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.